EMPEROR-Reduced · 2020 · New England Journal of Medicine
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Empagliflozin reduces cardiovascular death or heart-failure hospitalization in HFrEF regardless of diabetes status.
Source publication
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al. · New England Journal of Medicine · 2020
Sponsor
Boehringer Ingelheim
Principal investigator
Boehringer Ingelheim
Population
Heart Failure; n=3730
Primary endpoint
Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$1.5M / $3.0M
48%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1